Increased competition in the orphan drug market could ultimately help pull down prices, OptumRx suggests in a new report.
According to the report, roughly 40 percent of drugs approved this year will be orphan drugs.
“What is new is that we now are starting to see the development of orphan drugs become more competitive, increasing the potential for reduced costs and broader patient accessibility,” OptumRx Chief Medical Officer Sumit Dutta writes.
To read OptumRx’s report, click here.
To read FierceHealthcare’s coverage of the report, click here.